<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article298</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/EMILIA" style="display:block; margin-bottom:10px;">EMILIA Original</a></li>
<h2><strong>EMILIA</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer". <br/>
The New England Journal of Medicine. 2012. PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does Trastuzumab Emtansine (T-DM1) prolong progression-free and overall survival compared to lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Trastuzumab Emtansine (T-DM1) significantly improved progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
This trial influenced clinical practice and treatment guidelines by providing evidence for the use of T-DM1 as a treatment option in HER2-positive advanced breast cancer.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, randomized, open-label, phase 3 trial.<br/>
- N=991 patients with HER2-positive unresectable locally advanced or metastatic breast cancer.<br/>
- T-DM1 (n=495) vs. Lapatinib plus Capecitabine (n=496).<br/>
- Stratification factors included world region, prior chemotherapy regimens for advanced disease, and disease involvement (visceral vs. nonvisceral).<br/>
- Median follow-up: approximately 13 months (progression-free survival), 19 months (overall survival).<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion criteria: Progression on or after most recent treatment for advanced disease or within 6 months after adjuvant therapy, HER2-positive status confirmed by central laboratory.<br/>
- Exclusion criteria: Prior treatment with T-DM1, lapatinib, or capecitabine; significant cardiovascular disease; CNS metastases.<br/>
- Median age: 53 years<br/>
- Median duration of follow-up: 19.1 months for the primary analysis of overall survival.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- T-DM1 at 3.6 mg/kg IV every 21 days.<br/>
- Lapatinib at 1250 mg orally once daily plus Capecitabine at 1000 mg/m^2 orally every 12 hours on days 1-14 of a 21-day cycle.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary Outcomes: <br/>
  - Independent review assessed progression-free survival: 9.6 months (T-DM1) vs 6.4 months (control) (HR 0.65; 95% CI, 0.55-0.77; P&lt;0.001).<br/>
  - Overall survival at second interim analysis: 30.9 months (T-DM1) vs 25.1 months (control) (HR 0.68; 95% CI, 0.55-0.85; P&lt;0.001).<br/>
- Secondary Outcomes:<br/>
  - Investigator-assessed progression-free survival: 9.4 months (T-DM1) vs 5.8 months (control) (HR 0.66; P&lt;0.001).<br/>
  - Objective response rate: 43.6% (T-DM1) vs 30.8% (control) (P&lt;0.001).<br/>
  - Time to symptom progression was delayed in T-DM1 group.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Open-label design may introduce bias.<br/>
- Certain subgroups had less definitive benefits.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Funded by F. Hoffmann–La Roche/Genentech, a member of the Roche Group.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
